サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467655

希少疾病用医薬品市場レポート：薬剤タイプ、疾患タイプ、フェーズ、売れ筋医薬品、流通チャネル、地域別、2024～2032年

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
希少疾病用医薬品市場レポート：薬剤タイプ、疾患タイプ、フェーズ、売れ筋医薬品、流通チャネル、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の希少疾病用医薬品市場規模は、2023年に2,148億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて10.5%の成長率（CAGR）を示し、2032年までに5,413億米ドルに達すると予測しています。

希少疾病用医薬品とは、希少疾患の診断、予防、治療に用いられる医薬品を指します。これらの医薬品は、特定の公衆衛生上の要件を満たすために製造され、少数の患者グループ向けに製造されるため、通常、市場は限られています。これらの医薬品は、多くの腫瘍学的、代謝学的、血液学的、免疫学的、感染学的、神経学的疾患に対して有効です。リンパ腫、白血病、嚢胞性線維症、神経膠腫、膵臓がん、卵巣がん、多発性骨髄腫、腎細胞がんなどの医療的疾患は、多くの場合、生命を脅かし、慢性で進行性、退行性、障害性であり、特定の症状に有効な特定の治療法が必要とされます。

希少疾病用医薬品市場の動向：

がんやその他の希少遺伝性疾患の有病率の増加は、市場の成長を促す重要な要因のひとつです。製薬メーカーは、患者に個別化治療を提供するため、革新的な希少疾病用医薬品を開発しています。また、オーファンドラッグの利点に関する大衆の意識の高まりも市場を牽引しています。新しい医薬品メーカーの出現や、伝染病の蔓延を抑制するための政府の有利な政策の実施も、市場の成長に寄与しています。さらに、生物学的オーファンドラッグの開発など、さまざまな製品革新も成長を促す要因となっています。これらの医薬品は、がんなどの疾患を治療し、幹細胞に生じた損傷を回復させることができるため、全体的な需要を大幅に促進しています。その他の要因としては、医療インフラの改善、広範な研究開発活動などがあり、市場をさらに牽引すると予想されます。

本レポートで扱う主要質問

  • 2023年の希少疾病用医薬品の世界市場規模は？
  • 2024～2032年の世界の希少疾病用医薬品市場の予想成長率は？
  • 世界の希少疾病用医薬品市場を牽引する主要因は何か？
  • COVID-19が世界の希少疾病用医薬品市場に与えた影響は？
  • 薬剤タイプ別の世界の希少疾病用医薬品市場の内訳は？
  • 希少疾病用医薬品の世界市場の疾病タイプ別区分は？
  • 世界の希少疾病用医薬品市場の売れ筋医薬品別区分は？
  • 希少疾病用医薬品の世界市場の販売チャネル別区分は？
  • 希少疾病用医薬品の世界市場における主要地域は？
  • 希少疾病用医薬品の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 希少疾病用医薬品の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • 生物製剤
  • 非生物製剤

第7章 市場内訳：疾患タイプ別

  • オンコロジー
  • ヘマトロジー
  • 神経内科
  • 循環器
  • その他

第8章 市場内訳：フェーズ別

  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第9章 市場内訳：売れ筋医薬品別

  • レブラミド
  • リツキサン
  • コパキソン
  • オプジーボ
  • キイトルーダ
  • インブルビカ
  • アボネックス
  • センシパー
  • ソリリス
  • その他

第10章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンラインストア
  • その他

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Alexion Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • Jazz Pharmaceuticals Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd
図表

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2023
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2023
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2024-2032
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2024-2032
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players
目次
Product Code: SR112024A2382

The global orphan drugs market size reached US$ 214.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.3 Billion by 2032, exhibiting a growth rate (CAGR) of 10.5% during 2024-2032.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

Biological

Non-Biological

Breakup by Disease Type:

Oncology

Hematology

Neurology

Cardiovascular

Others

Breakup by Phase:

Phase I

Phase II

Phase III

Phase IV

Breakup by Top Selling Drugs:

Revlimid

Rituxan

Copaxone

Opdivo

Keytruda

Imbruvica

Avonex

Sensipar

Soliris

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1. What was the size of the global orphan drugs market in 2023?
  • 2. What is the expected growth rate of the global orphan drugs market during 2024-2032?
  • 3. What are the key factors driving the global orphan drugs market?
  • 4. What has been the impact of COVID-19 on the global orphan drugs market?
  • 5. What is the breakup of the global orphan drugs market based on the drug type?
  • 6. What is the breakup of the global orphan drugs market based on the disease type?
  • 7. What is the breakup of the global orphan drugs market based on top selling drugs?
  • 8. What is the breakup of the global orphan drugs market based on the distribution channel?
  • 9. What are the key regions in the global orphan drugs market?
  • 10. Who are the key players/companies in the global orphan drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orphan Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Phase

  • 8.1 Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

  • 9.1 Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7 Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8 Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9 Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10 Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Alexion Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Amgen Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Biogen Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Bristol Myers Squibb Company
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 Jazz Pharmaceuticals Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Sanofi S.A.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Takeda Pharmaceutical Company Limited
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis
    • 16.3.14 Teva Pharmaceutical Industries Ltd
      • 16.3.14.1 Company Overview
      • 16.3.14.2 Product Portfolio
      • 16.3.14.3 Financials
      • 16.3.14.4 SWOT Analysis